Anticancer Activities of Hesperidin via Suppression of Up-Regulated Programmed Death-Ligand 1 Expression in Oral Cancer Cells.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
02 Sep 2021
Historique:
received: 23 07 2021
revised: 22 08 2021
accepted: 24 08 2021
entrez: 10 9 2021
pubmed: 11 9 2021
medline: 11 11 2021
Statut: epublish

Résumé

Up-regulated expression of programmed death-ligand 1 (PD-L1) by interferon-gamma (IFN-γ) has been associated with promotion of cancer cell survival and tumor cell escape from anti-tumor immunity. Therefore, a blockade of PD-L1 expression can potentially be used as a molecular target for cancer therapy. The aim of this study was to investigate whether suppression of IFN-γ induced PD-L1 expression in two oral cancer cell lines, HN6 and HN15, by hesperidin effectively decreased cell proliferation and migration. Further, our objective was to elucidate the involvement of the signal transducer and activator of transcription 1 (STAT1) and STAT3 in the inhibition of induced PD-L1 expression by hesperidin. Our findings indicate that IFN-γ induced expression of PD-L1 protein in HN6 and HN15 via phosphorylation of STAT1 and STAT3 and that hesperidin significantly reduced that induction through suppression of phosphorylated STAT1 and STAT3 in both cell lines. Moreover, hesperidin also significantly decreased the viability, proliferation, migration, and invasion of both cell lines. In conclusion, hesperidin exerted anticancer effects against oral cancer cells through the suppression of PD-L1 expression via inactivation of the STAT1 and STAT3 signaling molecules. The findings of this study support the use of hesperidin as a potential adjunctive treatment for oral cancer.

Identifiants

pubmed: 34500779
pii: molecules26175345
doi: 10.3390/molecules26175345
pmc: PMC8434411
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
B7-H1 Antigen 0
CD274 protein, human 0
Immune Checkpoint Inhibitors 0
Hesperidin E750O06Y6O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Biol Chem. 2004 Oct 1;279(40):41679-85
pubmed: 15284232
Cell Oncol (Dordr). 2019 Apr;42(2):237-242
pubmed: 30680705
Tumour Biol. 2016 Jan;37(1):227-37
pubmed: 26194866
J Immunother Cancer. 2019 Nov 15;7(1):305
pubmed: 31730010
Head Neck. 2013 Oct;35(10):1404-9
pubmed: 22972608
Int J Cancer. 2000 May 1;86(3):307-17
pubmed: 10760816
PLoS One. 2014 Feb 14;9(2):e88557
pubmed: 24551119
Int J Mol Med. 2018 Jan;41(1):464-472
pubmed: 29138795
J Chromatogr A. 1998 Mar 13;799(1-2):101-10
pubmed: 9550103
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Int Immunopharmacol. 2018 Jan;54:39-45
pubmed: 29100036
Int J Dent. 2017;2017:5815493
pubmed: 28638410
Crit Rev Ther Drug Carrier Syst. 2016;33(4):363-400
pubmed: 27910740
Adv Immunol. 2007;96:41-101
pubmed: 17981204
Molecules. 2020 Jan 08;25(2):
pubmed: 31936263
Phytother Res. 2010 Jan;24 Suppl 1:S15-9
pubmed: 19548283
J Clin Oncol. 2018 Jan 20;36(3):262-267
pubmed: 29182497
J Exp Clin Cancer Res. 2018 Oct 29;37(1):261
pubmed: 30373602
Ther Adv Med Oncol. 2018 Jan 18;10:1758834017749748
pubmed: 29383037
Cell Death Dis. 2020 Jul 6;11(7):506
pubmed: 32632098
Exp Biol Med (Maywood). 2020 Mar;245(5):486-497
pubmed: 32050794
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Asian Pac J Trop Biomed. 2014 Mar;4(3):228-33
pubmed: 25182442
Molecules. 2018 Aug 18;23(8):
pubmed: 30126206
Cancer Med. 2018 Aug;7(8):4004-4011
pubmed: 29992764
Neoplasia. 2017 Apr;19(4):346-353
pubmed: 28319808
Cancer Cell. 2016 Dec 12;30(6):925-939
pubmed: 27866850
Toxicol Lett. 2009 Feb 10;184(3):204-10
pubmed: 19110045
Oral Oncol. 2012 Sep;48(9):775-9
pubmed: 22520054
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Immunobiology. 2012 Apr;217(4):385-93
pubmed: 22204817
Nat Med. 2018 Dec;24(12):1877-1886
pubmed: 30374200
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Br J Cancer. 1981 Jun;43(6):772-85
pubmed: 7195729
Cancer Res. 2020 Oct 1;80(19):4129-4144
pubmed: 32816860
J Periodontal Res. 2010 Aug;45(4):464-70
pubmed: 20337883
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846

Auteurs

Benjawan Wudtiwai (B)

Thailand Excellence Center for Tissue Engineering and Stem Cells, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

Anupong Makeudom (A)

Center of Excellence in Oral and Maxillofacial Biology, Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Chiang Mai 50200, Thailand.
School of Dentistry, Mae Fah Luang University, Chiang Rai 57100, Thailand.

Suttichai Krisanaprakornkit (S)

Center of Excellence in Oral and Maxillofacial Biology, Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Chiang Mai 50200, Thailand.

Peraphan Pothacharoen (P)

Thailand Excellence Center for Tissue Engineering and Stem Cells, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

Prachya Kongtawelert (P)

Thailand Excellence Center for Tissue Engineering and Stem Cells, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH